Friday, November 20, 2015
Thermo Fisher Scientific has opened a new state-of-the-art GMP facility in Singapore. The company, which established its first clinical services facility there in 2001, said the move to the newly built facility will meet the growing demand for clinical supply services in the region. The new site will provide both regional and global pharmaceutical and biotech companies with a one-stop service for clinical supplies—from GMP storage, local labeling, secondary packaging, comparator sourcing, handling and distribution of ambient and cold chain supplies to returns management.
Thermo Fisher Scientific has entered into a long-term agreement with Novartis and Pfizer to develop and commercialize a multi-marker, universal next-generation sequencing (NGS) oncology test that will serve as a companion diagnostic (CDx) for non-small cell lung cancer (NSCLC) across multiple drug development programs.
Parexel International, a global biopharmaceutical services provider, has enhanced its end-to-end clinical development services through a new process called Clinical Development Optimization. The Parexel Clinical Development Optimization process uses advanced technology to help expedite drug development through all four critical stages of clinical development—design, startup, trial execution and submission.
BioDuro, a global CRO leader focused on preclinical chemistry, biology, and fully outsourced integrated drug development services for pharmaceutical partners, has announced the merger of its U.S. operations with Formex, a provider of pharmaceutical API formulation, development and cGMP manufacturing.
Parexel International, a global biopharmaceutical services provider, and Kyoto Pharmaceutical University (KPU), a private pharmacy and science university, have announced a new joint program for clinical research and clinical trial management. The academic program offers undergraduate students an accredited, seven-week course designed to prepare them for careers in the biopharmaceutical industry.